Today: 9 June 2026
Visa stock down today as analysts see shifting Credit Card Competition Act risk ahead of earnings
27 January 2026
2 mins read

Visa stock down today as analysts see shifting Credit Card Competition Act risk ahead of earnings

New York, Jan 27, 2026, 11:29 (EST) — Regular session

  • Visa shares dipped roughly 0.9% by mid-morning, with Mastercard and American Express also retreating
  • Morgan Stanley flags a political hurdle for the Credit Card Competition Act
  • Cantor Fitzgerald kicks off coverage of Visa with an Overweight rating and sets a $400 price target; earnings are expected on Jan. 29

Visa Inc shares dropped roughly 0.9%, hitting $325.56 in late morning trading Tuesday. Mastercard declined 0.5%, while American Express slid 1.4%.

Traders are weighing two immediate factors: Visa’s quarterly earnings set for later this week, and new developments in Washington concerning credit-card fees and routing.

Payment networks are on edge over any sign that lawmakers might push for greater competition in credit-card transaction routing. This matters because it can cut into the fees they collect each time a transaction goes through the network.

Morgan Stanley analyst James Faucette said sentiment around Visa and Mastercard has brightened following what he described as a political setback for the Credit Card Competition Act (CCCA). He pointed to a Politico report revealing Senator Roger Marshall “agreed not to offer a credit card amendment” during Senate Agriculture Committee markup, reducing the chance the bill will be tied to advancing legislation. Faucette noted this development “should assuage near-term fears” and “makes the networks easier to buy.” Morgan Stanley’s downside scenario had assumed a 10% shift of U.S. credit volumes to alternative networks and roughly 25% price pressure on U.S. credit fees, translating into about a 3.5% drag on Visa’s 2026 revenue estimates. Investing.com

Durbin and Marshall brought the CCCA back this month, pitching it as a move to boost competition in the credit-card space. The proposed law would force banks over a certain size to support at least two unaffiliated card networks on their credit cards, with at least one being outside the Visa and Mastercard duopoly.

Cantor Fitzgerald’s Ramsey El-Assal kicked off coverage on Visa with an Overweight rating and set a $400 price target. Overweight signals the expectation that Visa will outperform its peers. Cantor highlighted the ongoing global move from paper to electronic payments, noting that Visa’s value-added services and “new flows” broaden its addressable market and help “future-proof the model.” Benzinga

Visa plans to release its fiscal first-quarter results after the market closes on Jan. 29, followed by an audio webcast at 5 p.m. Eastern. Investors will zero in on cross-border volumes, seen as a gauge of travel and international spending, along with “client incentives” — the payments and rebates Visa offers banks and partners that lower its reported revenue. Visa Investor Relations

The legislative talk has been chaotic. According to the American Bankers Association’s Banking Journal, Marshall suggested inserting the routing language into a cryptocurrency market-structure bill slated for the Senate Agriculture Committee.

Any renewed effort could still challenge the networks’ capacity to set U.S. credit fees, even if the final legislation diverges from earlier drafts. Visa is also fending off a Justice Department lawsuit accusing it of illegally monopolizing the U.S. debit network market.

Thursday’s earnings report and management’s take on volumes, incentives, and policy will be the next major catalyst. Until then, Visa’s shares will probably bounce around, driven by interest rates, consumer spending data, and the latest Washington news.

Stock Market Today

  • Glaukos (GKOS) Shares Show Volatility Amid 19% Undervaluation Claim
    June 9, 2026, 9:42 AM EDT. Glaukos (GKOS) shares rose 18% in the past week but fell nearly 9% over the last month, reflecting short-term volatility. The stock trades at $121.96, below its fair value estimate of $151.08, suggesting a 19.3% undervaluation. The company's focus on ophthalmic therapies, including iDose TR for glaucoma, underpins a potential shift in treatment approaches driven by an aging population and increasing glaucoma cases. Investors consider this a long-term growth opportunity, though realization depends on product adoption and reimbursement policies. Glaukos posted a one-year total shareholder return of 28.87%, indicating sustained momentum despite recent fluctuations. The valuation hinges on expectations of revenue growth, profitability turnaround, and premium earnings multiples typical of high growth firms.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps
Previous Story

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom
Next Story

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom

Go toTop